Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities
Authors
Keywords
-
Journal
Molecular Oncology
Volume 9, Issue 5, Pages 1034-1041
Publisher
Wiley
Online
2014-10-16
DOI
10.1016/j.molonc.2014.10.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management
- (2016) F. Reed Johnson et al. JOURNAL OF MANAGED CARE PHARMACY
- Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
- (2014) D. R. Parkinson et al. CLINICAL CANCER RESEARCH
- Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union
- (2014) F. Pignatti et al. CLINICAL CANCER RESEARCH
- Implementing personalized cancer care
- (2014) Richard L. Schilsky Nature Reviews Clinical Oncology
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Balancing benefit and risk of medicines: a systematic review and classification of available methodologies
- (2014) Shahrul Mt-Isa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Reevaluating the Accelerated Approval Process for Oncology Drugs
- (2013) W. H. Wilson et al. CLINICAL CANCER RESEARCH
- Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
- (2012) K. Thornton et al. CLINICAL CANCER RESEARCH
- Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
- (2012) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
- (2011) Francesco Pignatti et al. CLINICAL CANCER RESEARCH
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- Role of randomized phase III trials in an era of effective targeted therapies
- (2011) Manish R. Sharma et al. Nature Reviews Clinical Oncology
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Application of the BRAT Framework to Case Studies: Observations and Insights
- (2010) B S Levitan et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
- (2010) R. Sridhara et al. JNCI-Journal of the National Cancer Institute
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safe Drugs and the Cost of Good Intentions
- (2009) Hans-Georg Eichler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- NICE at 10 years: new challenges ahead
- (2009) Peter Littlejohns Expert Review of Pharmacoeconomics & Outcomes Research
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
- (2008) Hans-Georg Eichler et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More